Metabolites

Journal Browser

► Journal Browser

Key Role of Drug Intervention on Diabetic Complications

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Pharmacology and Drug Metabolism".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 4919

Share This Special Issue

Special Issue Editor

Dr. Nehal Elsherbiny

E-Mail Website
Guest Editor

Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
Interests: diabetes mellitus; cancer; stem cell therapy; cell signalling; drug toxicity

Special Issue Information

Dear Colleagues,

Diabetes mellitus—a global alarmingly increasing metabolic disease—is associated with macro- and microvascular complications that adversely affect the quality of life of diabetic patients, causing increased morbidity and mortality, and posing substantial burdens to healthcare systems. Various factors other than hyperglycaemia can trigger diabetes-induced complications and are proposed as underlying pathogenic mechanisms. Therefore, targeting these pathways could be a promising therapeutic strategy for such diabetic associated lesions. Currently, in addition to insulin therapy, various treatments are used to control blood sugar through different mechanisms, such as increasing peripheral absorption of glucose, enhancement of insulin secretion and delaying carbohydrate absorption. Recently, glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors have shown promising therapeutic efficacies in diabetic patients. High prevalence of diabetes worldwide highlights the urgent need for effective therapies.

This Special Issue welcomes submissions of studies in the field of diabetes pharmacotherapy, focusing on combating diabetic complications. Preclinical, clinical, and bioinformatics studies relevant to the field will be considered.

Dr. Nehal Elsherbiny
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Diabetic Complications
Pharmacotherapy
Therapeutic Target
Clinical
Experimental

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

22 pages, 29216 KiB

Open AccessArticle

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms

by Mamdouh Eldesoqui, Zienab Helmy Eldken, Sally Abdallah Mostafa, Rasha Hamed Al-Serwi, Mohamed El-Sherbiny, Nehal Elsherbiny, Zuhair M. Mohammedsaleh and Noha Hammad Sakr

Metabolites 2022, 12(7), 635; https://doi.org/10.3390/metabo12070635 - 11 Jul 2022

Cited by 7 | Viewed by 2490

Abstract

One of the most prevalent cardiovascular problems linked with type 2 diabetes mellitus (T2DM) is diabetic cardiomyopathy (DCM). DCM is associated with myocardial oxidative stress, inflammation, apoptosis, suppressed autophagy, extracellular matrix remodeling, and fibrosis. The current study aims to investigate the protective effect of sodium-glucose transport 2 inhibitor (SGLT2i) dapagliflozin and/or exercise on DCM. Thirty adult male Sprague Dawley rats are used. T2DM is induced by a 6-week high-fat diet (HFD) followed by a single intraperitoneal (IP) injection of 35 mg/kg streptozotocin (STZ). Rats are divided into five groups, control, diabetic (DM), DM + swimming, DM + dapagliflozin, and DM + dapagliflozin and swimming. Serum glucose, insulin, insulin resistance (HOMA-IR), and cardiac enzymes (CK-MB and lactate dehydrogenase (LDH) are measured. Heart specimens are used for evaluation of cellular oxidative stress markers malondialdehyde (MDA), antioxidant enzymes, glutathione (GSH), and catalase (CAT), as well as mRNA expression of TGF-β, MMP9, IL-1β, and TNF-α. Stained sections with haematoxylin and eosin (H & E) and Masson trichrome are used for histopathological evaluation and detection of fibrosis, respectively. Immunohistochemical staining for apoptosis (caspase-3), and autophagy (LC3) are also carried out. The combinations of SGLT2i and exercise exhibited the most significant cardioprotective effect. It improved diabetic-induced histopathological alterations in the myocardium and attenuated the elevation of serum blood glucose, CK-MB, LDH, myocardial MDA, and mRNA expression of TNF-α, IL-1β, TGF-β, MMP9, and the immune expression of caspase-3. Moreover, this combination increased the serum insulin, myocardial antioxidants GSH and CAT, and increase the immune expression of the LC-3. In conclusion, a combination of SGLT2i and exercise exerted a better antioxidant, anti-inflammatory, and antifibrotic effect in DCM. Moreover, the combination enhances the autophagic capacity of the heart. Full article

(This article belongs to the Special Issue Key Role of Drug Intervention on Diabetic Complications)

► Show Figures

Graphical abstract

Review

Jump to: Research

24 pages, 732 KiB

Open AccessReview

Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives

by Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Gabriela Ștefănescu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu and Bogdan-Mircea Mihai

Metabolites 2023, 13(5), 581; https://doi.org/10.3390/metabo13050581 - 23 Apr 2023

Cited by 2 | Viewed by 1914

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease worldwide, reaching one of the highest prevalences in patients with type 2 diabetes mellitus (T2DM). For now, no specific pharmacologic therapies are approved to prevent or treat NAFLD. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are currently evaluated as potential candidates for NAFLD treatment in patients with T2DM. Some representatives of this class of antihyperglycemic agents emerged as potentially beneficial in patients with NAFLD after several research studies suggested they reduce hepatic steatosis, ameliorate lesions of nonalcoholic steatohepatitis (NASH), or delay the progression of fibrosis in this population. The aim of this review is to summarize the body of evidence supporting the effectiveness of GLP-1RA therapy in the management of T2DM complicated with NAFLD, describing the studies that evaluated the effects of these glucose-lowering agents in fatty liver disease and fibrosis, their possible mechanistic justification, current evidence-based recommendations, and the next steps to be developed in the field of pharmacological innovation. Full article

(This article belongs to the Special Issue Key Role of Drug Intervention on Diabetic Complications)

► Show Figures